V V GLUE AREAV

1187086A2

ZERIT (stavudine) ZERIT[®] (stavudine) Capsules ZERIT[®] (stavudine) for Oral Solution

(Patient Information Leaflet Included)



ZERIT® (stavudine)

ZERIT[®] (stavudine) Capsules ZERIT® (stavudine) for Oral Solution

Rx only

(Patient Information Leaflet Included)

WARNING

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS INCLUDING FATAL CASES HAVE BEEN REPORTED WITH THE USE OF NUCLE OSIDE ANALOGUES ALONE OR IN COMBINATION. INCLUDING STAVUDINE AND OTHER ANTIRETROVIRALS, FATAL LACTIC ACIDOSIS HAS BEE REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION O STAVIIDINE AND DIDANOSINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF STAVUDINE AND DIDANOSINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK (SEE WARNINGS AND PRECAUTIONS: PREGNANCY).


FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WHEN ZERIT WAS PART OF A COMBINATION REGIMEN THAT INCLUDED DIDANOSINE, WITH OR WITHOUT HYDROXYUREA, IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, RÉGARDLESS OF DEGREE OF IMMUNOSUPPRESSION (SEE WARNINGS)

DESCRIPTION

ZERIT® is the brand name for stavudine (d4T), a synthetic thymidine nucleoside analogue, active against the human immunodeficiency virus (HIV)

ZERIT (stavudine) Capsules are supplied for oral administration in strengths of 15 20 30 and 40 mg of stayudine. Each cansule also contains inactive ingredients. microcrystalline cellulose, sodium starch alvcolate, lactose, and magnesium stearate. The hard gelatin shell consists of gelatin, silicon dioxide, sodium lauryl sulfate, titanium dioxide, and iron oxides. The capsules are printed with edible inks ZERIT (stavudine) for Oral Solution is supplied as a dve-free, fruit-flavored powder in bottles with child-resistant closures providing 200 ml of a 1 mg/ml stavudine solution upon constitution with water per label instructions. The powder for oral solution contains the following inactive ingredients: methylparaben propylparaben, sodium carboxymethylcellulose, sucrose, and antifoaming and flavoring agents.

The chemical name for stavudine is 2',3'-didehydro-3'-deoxythymidine Stavudine has the following structural formula:



Stavudine is a white to off-white crystalline solid with the molecular formul H₁₀N₂O₄ and a molecular weight of 224.2. The solubility of stayudine at 23° (approximately 83 mg/mL in water and 30 mg/mL in propylene glycol. The n-octanol/water partition coefficient of stavudine at 23° C is 0.144.

MICROBIOLOGY Mechanism of Action

Stavudine, a nucleoside analogue of thymidine, is phosphorylated by cellular kinases to the active metabolite stavudine triphosphate. Stavudine triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate thymidine triphosphate (K=0.0083 to 0.032 uM) and by causing DNA chain termination following its incorporation into viral DNA Stavudine triphosphate inhibits cellular DNA polymerases β and γ and markedly reduces the synthesis of mitochondrial DNA.

Antiviral Activity

The *in vitro* antiviral activity of stavudine was measured in peripheral blood mononuclear cells, monocytic cells, and lymphoblastoid cell lines. The concentration drug necessary to inhibit HIV-1 replication by 50% (IC₅₀) ranged fro 0.009 to 4 µM against laboratory and clinical isolates of HIV-1. In vitro, stavudine exhibited additive to antagonistic activity in combination with zidovudine Stavudine in combination with either abacavir didanosine tenofovir or zalcitabine exhibited additive to synergistic anti-HIV-1 activity. Ribavirin, at the 9-45 ul

oncentrations tested, reduced the anti-HIV-1 activity of stavudine by 2.5- to 5-fold. The relationship between in vitro susceptibility of HIV-1 to stavudine and the nhibition of HIV-1 replication in humans has not been established Drug Resistance

HIV-1 isolates with reduced susceptibility to stavudine have been selected in vitro (strain-specific) and were also obtained from patients treated with stavudine. Phenotypic analysis of HIV-1 isolates from 61 patients receiving prolonged (6-29 months) stavudine monotherapy showed that post-therapy isolates from our patients exhibited IC50 values more than 4-fold (range 7- to 16-fold) higher than the average pretreatment susceptibility of baseline isolates. Of these, HIV-1 isolates from one patient contained the zidovudine-resistance-associated mutations T215Y and K219E, and isolates from another patient contained the multiple-nucleoside-resistance-associated mutation Q151M. Mutations in the RT gene of HIV-1 isolates from the other two patients were not detected. The genetic basis for stavudine susceptibility changes has not been identified.

Cross-resistance

Cross-resistance among HIV-1 reverse transcriptase inhibitors has been observed Several studies have demonstrated that prolonged stavudine treatment can select and/or maintain mutations associated with zidovudine resistance. HIV-1 isolates with one or more zidovudine-resistance-associated mutations (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) exhibited reduced susceptibility to stavudine in vitro.

CLINICAL PHARMACOLOGY

Pharmacokinetics

The pharmacokinetics of stavudine have been evaluated in HIV-infected adult and pediatric patients (Tables 1-3). Peak plasma concentrations (Cmax) and area under the plasma concentration-time curve (AUC) increased in proportion to dose after both single and multiple doses ranging from 0.03 to 4 mg/kg. There was no significant accumulation of stavudine with repeated administration every 6, 8, or 2 hours

Following oral administration stavudine is rapidly absorbed with peak plasma concentrations occurring within 1 hour after dosing. The systemic exposure to udine is the same following administration as capsules or solution. Steadystate pharmacokinetic parameters of ZERIT (stavudine) in HIV-infected adults are shown in Table 1

Steady-State Pharmacokinetic Parameters of ZERIT in HIV-Infected Adults

Parameter	ZERIT 40 mg BID Mean ± SD (n=8)
AUC (ng•h/mL) ^a	2568 ± 454
C _{max} (ng/mL)	536 ± 146
C _{min} (ng/mL)	8 ± 9
a from 0 to 24 hours. AUC = area under the curve over 24 hours. C_{max} = maximum plasma concentration. C_{min} = trough or minimum plasma concentration.	tion.

Distribution

Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 µg/mL. Stavudine distributes equally between red blood cells and plasma. Volume of distribution is shown in Table 2.

The metabolism of stavudine has not been elucidated in humans

Flimination In humans, renal elimination accounts for about 40% of the overall clearance regardless of the route of administration (Table 2). The mean renal clearance was about twice the average endogenous creatinine clearance, indicating active tubular

renal impairment. The mean ± SD hemodialvsis clearance value of stavudine was 120 ± 18 mL/min (n=12); the mean \pm SD percentage of the stavudine dose recovered in the dialysate, timed to occur between 2-6 hours post-dose, was 31 + 5%. Based on these observations, it is recommended that ZERIT (stavudine) dosage be modified in patients with reduced creatinine clearance and in patients secretion in addition to glomerular filtration. The remaining 60% of the drug is receiving maintenance hemodialysis (see DOSAGE AND ADMINISTRATION). presumably eliminated by endogenous pathways.

Pharmacokinetic Parameters of Stavudine in HIV-Infected Adults Bioavailability, Distribution, and Clearance

Parameter	Mean ± SD	n
Oral bioavailability (%)	86.4 ± 18.2	25
Volume of distribution (L) ^a	46 ± 21	44
Total body clearance (mL/min) ^a	594 ± 164	44
Apparent oral clearance (mL/min) ^b	560 ± 182°	113
Renal clearance (mL/min) ^a	237 ± 98	39
Elimination half-life, IV dose (h) ^a	1.15 ± 0.35	44
Elimination half-life, oral dose (h) ^b	1.6 ± 0.23	8
Urinary recovery of stavudine (% of dose) ^{a,d}	42 ± 14	39
^a following 1-hour IV infusion. ^b following single oral dose. ^c assuming a body weight of 70 kg. ^d over 12-24 hours.		

Special Populations Pediatric

Table 3

Volume of

istribution (L/kg)^a

Ratio of CSF:plasma

tal body clearanc

_/min/kg)^a

limination half-life

imination half-life

Jrinary recovery of

over 8 hours

ND = not determine

Renal Impairment

stavudine (% of dose

a following 1-hour IV infusion

following single oral dose.

IV dose (h)^a

oral dose (h)^c

parent oral clearance

For pharmacokinetic properties of stavudine in pediatric patients see Table 3.

Jes 5 weeks Ages 14 Day o 15 years n to 28 days n of Birth

13.75 ± 4.29 20 11.52 ± 5.93 30 5.08 ± 2.80 17

0.96 ± 0.26 20 1.59 ± 0.29 30 5.27 ± 2.01 17

ND

Pharmacokinetic Parameters (Mean ± SD) of Stavudine in

76.9 ± 31.7 20

0.73 ± 0.32 21

59 ± 35 8 ND

9.75 ± 3.76 21 ND

1 11 + 0 28 21 ND

t median time of 2.5 hours (range 2-3 hours) following multiple oral doses.

Data from two studies in adults indicated that the apparent oral clearance of

stavudine decreased and the terminal elimination half-life increased as creatinine

clearance decreased (see Table 4). C_{max} and T_{max} were not significantly altered by

34 ± 16

Aaes 5 weeks

HIV-Exposed or -Infected Pediatric Patients

Creatinine o

(mL/min

Apparent or

clearance (

Renal cleara

(mL/min)

a Single 40-

 $_{1/2}$ (h)

and 4 other) should be avoided

(see WARNINGS) pathways.



a 12 a

Mean ± SD Pharmacokinetic Parameter Values of ZERIT^a in Adults with Varying Degrees of Renal Function

ig bogi	ooo or monut	ranotion		
	Creat			
	>50 mL/min (n=10)	26-50 mL/min (n=5)	9-25 mL/min (n=5)	Hemodialysis Patients ^b (n=11)
learance al	104 ± 28	41 ± 5	17 ± 3	NA
(mL/min) ince) 335 ± 57	191 ± 39	116 ± 25	105 ± 17
	167 ± 65 1.7 ± 0.4	73 ± 18 3.5 ± 2.5	17 ± 3 4.6 ± 0.9	NA 5.4 ± 1.4
mg oral d while	dose.	off dialucia		

^b Determined while patients were off dialysis

1/2 = terminal elimination half-life. NA = not applicable.

Hepatic Impairment

Stavudine pharmacokinetics were not altered in five non-HIV-infected patients with henatic impairment secondary to cirrhosis (Child-Pugh classification B or C) following the administration of a single 40-mg dose.

Stavudine pharmacokinetics have not been studied in patients >65 years of age. (See PRECAUTIONS: Geriatric Use.)

A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-infected patients showed no clinically important differences between males (n=291) and females (n=27).

A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-infected patients showed no clinically important differences between races (n=233 Caucasian, 39 African-American, 41 Hispanic, 1 Asian,

Drug Interactions (see PRECAUTIONS: Drug Interactions)

Zidovudine: Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with ZERIT (stavudine)

Doxorubicin: In vitro data indicate that the phosphorylation of stavudine is inhibited at relevant concentrations by doxorubicin

Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine. stavudine, and zidovudine. However, no pharmacokinetic (eq. plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodvnamic (eq. loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18) stavudine (n=10) or zidovudine (n=6) were coadministered as part of a multi-drug regimen to HIV/HCV co-infected patients

Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2 CYP2C9 CYP2C19. CYP2D6. and CYP3A4: therefore, it is unlikely that clinically significant drug interactions will occur with drugs metabolized through these

Because stayudine is not protein-bound, it is not expected to affect the pharma cokinetics of protein-bound drugs

Tables 5 and 6 summarize the effects on AUC and C_{max} , with a 95% confidence interval (CI) when available, following coadministration of ZERIT with didanosine. lamivudine, and nelfinavir. No clinically significant pharmacokinetic interactions were observed.

Results of Drug Interaction Studies with ZERIT: Effects of Coadministered Drug on Stavudine Plasma AUC and Cmax Values AUC of Stavudine Stavudin (95% CI) (95% CI) Dosage Didanosine, 100 mg 40 mg q12h 10 17% \leftrightarrow q12h for 4 days for 4 days 12% Lamivudine, 150 mg 40 mg single 18 (92.7-100.6%) (100.3-126.1%) single dose dose Nelfinavir, 750 mg 30-40 mg q12h 8 \leftrightarrow \leftrightarrow a8h for 56 davs for 56 days indicates increase. \rightarrow indicates no change, or mean increase or decrease of <10%. ^a HIV-infected patients.

Results of Drug Interaction Studies with ZERIT: Effects of Stavudine of Coadministered Drug Plasma AUC and C_{max} Values

Drug	Stavudine Dosage	nª	Coadministered Drug (95% Cl)	Coadministered Drug (95% CI)
Didanosine, 100 mg q12h for 4 days	40 mg q12h for 4 days	10	\leftrightarrow	\leftrightarrow
Lamivudine, 150 mg single dose	40 mg single dose	18	↔ (90.5-107.6%)	↔ (87.1-110.6%)
Nelfinavir, 750 mg q8h for 56 days	30-40 mg q12h for 56 days	8	\leftrightarrow	\leftrightarrow

INDICATIONS AND USAGE

ZERIT (stayudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection (see Clinical Studies

Clinical Studies

Combination Therany The combination use of ZERIT is based on the results of clinical studies in HIV-infected patients in double- and triple-combination regimens with other antiretroviral agents

One of these studies (START 1) was a multicenter randomized open-label study comparing ZERIT (40 mg twice daily) plus lamiyudine plus indinavir to zidovudine plus lamivudine plus indinavir in 202 treatment-naive patients. Both regimens resulted in a similar magnitude of inhibition of HIV RNA levels and creases in CD4 cell counts through 48 weeks

Monotherapy

The efficacy of ZEBIT was demonstrated in a randomized, double-blind study (Al455-019, conducted 1992-1994) comparing ZERIT with zidovudine in 822 patients with a spectrum of HIV-related symptoms. The outcome in terms of progression of HIV disease and death was similar for both drugs

CONTRAINDICATIONS

ZERIT is contraindicated in patients with clinically significant hypersensitivity to stavudine or to any of the components contained in the formulation.

1. Lactic Acidosis/Severe Hepatomegaly with Steatosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Although relative rates of lactic acidosis have not been assessed in prospective well-controlle trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. Female gender obesity and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see PRECAUTIONS: Pregnancy).

articular caution should be exercised when administering ZERIT to any patien with known risk factors for liver disease: however cases of lactic acidosis have also been reported in patients with no known risk factors. Generalized fatigue, diges tive symptoms (nausea, vomiting, abdominal pain, and unexplained weight loss); espiratory symptoms (tachypnea and dyspnea); or neurologic symptoms (including motor weakness, see 3. Neurologic Symptoms) might be indicative of the devel opment of symptomatic hyperlactatemia or lactic acidosis syndrome

Treatment with ZERIT (stavudine) should be suspended in any patient who develop clinical or laboratory findings suggestive of symptomatic hyperlactatemia, lactic acidosis, or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

Henatic Imnairment and Toxicity

The safety and efficacy of ZERIT have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroriral therapy, patients with preexisting liver dysfunction, including chronic active nepatitis, have an increased frequency of liver function abnormalities, including severe and potentially fatal henatic adverse events and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Use with Didanosine and Hydroxyurea-Based Regimens

n increased risk of hepatotoxicity may occur in patients treated with ZERIT bination with didanosine and hydroxyurea compared to when ZEBIT is use alone. Deaths attributed to hepatotoxicity have occurred in patients receiving thi bination. This combination should be avoide

Use with Interferon and Ribavirin-Based Regimens

In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as stayudine. Although no evidence of a pharmacokinetic or pharmacodynamic (eq. loss of HIV/HCV virologic suppression) interaction was seen when ribavirin was coadministered with stavudine in HIV/HCV co-infected patients (see CLINICAL PHARMACOLOGY: Drug Interactions). hepatic decompensation (some fatal) has occurred in HIV/HCV co-infected patients receiving combina tion antiretroviral therapy for HIV and interferon and ribavirin. Patients receiving interferon with or without ribavirin and stavudine should be closely monitore or treatment-associated toxicities, especially hepatic decompensation. Discontinuation of stavudine should be considered as medically appropriate. Dos reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eq. Child-Pugh >6) (see the complete prescribing information for interferon and ribavirin).

3. Neurologic Symptoms

Motor weakness has been reported rarely in patients receiving combination antiretroviral therapy including ZERIT. Most of these cases occurred in the setting of lactic acidosis. The evolution of motor weakness may mimic the linical presentation of Guillain-Barré syndrome (including respiratory failure) Symptoms may continue or worsen following discontinuation of therapy.

Peripheral neuropathy, manifested by numbness, tingling, or pain in the hands or feet has been reported in patients receiving ZEBIT therapy Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, with a history of neuropathy, or in patients receiving other drugs that have been associated with neuropathy, including didanosine (see ADVERSE REACTIONS). 4 Pancreatitis

Fatal and nonfatal pancreatitis have occurred during therapy when ZERI was part of a combination regimen that included didanosine, with or without hydroxyurea, in both treatment-naive and treatment-experienced patients, regardless of degree of immunosuppression. The combination of ZERIT and didanosine (with or without hydroxyurea) and any other agents that are toxic to the pancreas should be suspended in patients with suspected pancreatitis einstitution of ZERIT after a confirmed diagnosis of pancreatitis should be undertaken with particular caution and close patient monitoring. The new regimen should contain neither didanosine nor hydroxyurea.

RECAUTIONS Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving anti retroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including ZERIT. During the initial phase of ombination antiretroviral treatment, patients whose immune system responds hay develop an inflammatory response to indolent or residual opportunistic nfections (such as Mycobacterium avium infection cytomegalovirus Pneumocvstis iiroveci pneumonia (PCP), or tuberculosis), which may necessitate further evaluation and treatment

Patients should be informed of the importance of early recognition of symptoms of symptomatic hyperlactatemia or lactic acidosis syndrome, which include unexplained weight loss, abdominal discomfort, nausea, vomiting, fatigue, dyspnea and motor weakness. Patients in whom these symptoms develop should seel medical attention immediately. Discontinuation of ZERIT therapy may be required.

Patients should be informed that an important toxicity of ZERIT (stayudine) is peripheral neuropathy. Patients should be aware that peripheral neuropathy is nanifested by numbness, tingling, or pain in hands or feet, and that these symptoms should be reported to their physicians. Patients should be counseled that peripheral neuropathy occurs with greatest frequency in patients who have advanced HIV disease or a history of peripheral neuropathy, and that dose mod fication and/or discontinuation of ZERIT may be required if toxicity develops Caregivers of young children receiving ZERIT therapy should be instructed

egarding detection and reporting of peripheral neuropathy Patients should be informed that when ZERIT is used in combination with other

agents with similar toxicities, the incidence of adverse events may be higher than when ZERIT is used alone. An increased risk of pancreatitis, which may be fata may occur in patients treated with the combination of ZERIT and didanosine, with or without hydroxyurea. Patients treated with this combination should be closely monitored for symptoms of pancreatitis. An increased risk of hepatotoxi which may be fatal, may occur in patients treated with ZERIT in con

Patients should be informed that ZERIT (stavudine) is not a cure for HIV infection and that they may continue to acquire illnesses associated with HIV infection including opportunistic infections. Patients should be advised to remain under the care of a physician when using ZERIT. They should be advised that ZERIT therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Patients should be informed that the long-term effects of 7FBIT are unknown at this time

Patients should be informed that the Centers for Disease Control an Prevention (CDC) recommend that HIV-infected mothers not nurse newborn nfants to reduce the risk of postnatal transmission of HIV infection.

Patients should be informed that redistribution or accumulation of body fa may occur in individuals receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

Patients should be advised of the importance of adherence to any antiretrovira regimen, including those that contain ŻERIT.

Drug Interactions (see also CLINICAL PHARMACOLOGY)

vudine competitively inhibits the intracellular phosphorylation of stavudine herefore use of zidovudine in combination with ZERIT should be avoided

In vitro data indicate that the phosphorylation of stayudine is also inhibited a relevant concentrations by doxorubicin and ribavirin. The clinical significance of these in vitro interactions is unknown; therefore, concomitant use of stavuous wi either of these drugs should be undertaken with caution. (See WARNINGS)

Carcinogenesis, Mutagenesis, Impairment of Fertility

In 2-year carcinogenicity studies in mice and rats, stayudine was nongenic at doses which produced exposures (AUC) 39 and 168 times, respectively numan exposure at the recommended clinical dose. Benign and malignant live tumors in mice and rats and malignant urinary bladder tumors in there rat occurred at levels of exposure 250 (mice) and 732 (rats) times human er abosure at the recommended clinical dose.

Stavudine was not mutagenic in the Ames. E. coli reverse mutation or the CHO/HGPRT mammalian cell forward gene mutation assays, with and without netabolic activation. Stavudine produced positive results in the in vitro-umai ymphocyte clastogenesis and mouse fibroblast assays, and in the *in viv*e-mous micronucleus test. In the *in vitro* assays, stavudine elevated the frequency **E**chro mosome aberrations in human lymphocytes (concentrations of 25 to 250 dg/m without metabolic activation) and increased the frequency of transformer to i mouse fibroblast cells (concentrations of 25 to 2500 µg/mL, with and without metabolic activation). In the *in vivo* micro-nucleus assay, stavudine wa genic in bone marrow cells following oral stavudine administration to mice a dosages of 600 to 2000 mg/kg/day for 3 days.

No evidence of impaired fertility was seen in rats with exposures (based or Cmax) up to 216 times that observed following a clinical dosage of 1 mg/kg/day. Pregnanc

Pregnancy Category C. Reproduction studies have been performed in rate and rabbits with exposures (based on Cmax) up to 399 and 183 times, respectively, of that seen at a clinical dosage of 1 mg/kg/day and have revealed no evidence o teratogenicity. The incidence in fetuses of a common skeletal variation, unossified r incomplete ossification of sternebra, was increased in rats at 399 times huma exposure, while no effect was observed at 216 times human exposure. A slig nost-implantation loss was noted at 216 times the human exposure with no effect noted at approximately 135 times the human exposure. An increase in early ra neonatal mortality (birth to 4 days of age) occurred at 399 times the human exposure, while survival of neonates was unaffected at approximately 135 times the human exposure. A study in rats showed that stavudine is transferred to the

<u>5</u> 8 informatic ing ZERIT AZT I AZT I of ZEF É.⊑ ŏ

fetus through the placenta. The concentration in fetal tissue was approximately one-half the concentration in maternal plasma. Animal reproduction studies are not always predictive of human response

There are no adequate and well-controlled studies of stavudine in pregnant women. Stavudine should be used during pregnancy only if the potential benefit justifies the potential risk.

Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. It is unclear if pregnancy augments the risk of lactic acidosis/hepatic steatosis syndrome reported n nonpregnant individuals receiving nucleoside analogues (see WARNINGS: Lactic Acidosis/Severe Hepatomegaly with Steatosis). The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. Health more frequently in patients treated with ZERIT in combination with didanosine care providers caring for HIV-infected pregnant women receiving stavudine should be alert for early diagnosis of lactic acidosis/hepatic steatosis syndrome.

Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

Nursing Mothers

The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. Studies in lactating rats demonstrated that stavudine is excreted in milk Although it is not known whether stavudine is excreted in human milk, there exists the potential for adverse effects from stavudine in nursing infants. Because of both the notential for HIV transmission and the notential for serious adverse reactions in nursing infants, mothers should be instructed not to breast-feed if they are receiving ZERIT.

Pediatric Use

Use of stavudine in pediatric patients from birth through adolescence is supported by evidence from adequate and well-controlled studies of stavudine in adults with additional pharmacokinetic and safety data in pediatric patients

Adverse events and laboratory abnormalities reported to occur in pediatric patients in clinical studies were generally consistent with the safety profile of stavudine in adults. These studies include ACTG 240, where 105 pediatric patients ages 3 months to 6 years received ZERIT 2 mg/kg/day for a median of 6.4 months; a controlled clinical trial where 185 newborns received ZERIT 2 mg/kg/day either alone or in combination with didanosine from birth through 6 weeks of age and a clinical trial where 8 newborns received ZERIT 2 mg/kg/day in combination with didanosine and nelfinavir from birth through 4 weeks of age

Stavudine pharmacokinetics have been evaluated in 25 HIV-infected pediatric patients ranging in age from 5 weeks to 15 years and in weight from 2 to 43 kg after IV or oral administration of single doses and twice-daily regimens and in 30 HIV-exposed or -infected newborns ranging in age from birth to 4 weeks after oral administration of twice-daily regimens (see CLINICAL PHARMACOLOGY, Table 3). Geriatric Use

Clinical studies of ZERIT (stavudine) did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Greater sensitivity of some older individuals to the effects of ZERIT cannot be ruled out.

In a monotherapy Expanded Access Program for patients with advanced HIV infec tion, peripheral neuropathy or peripheral neuropathic symptoms were observed in 15 of 40 (38%) elderly patients receiving 40 mg twice daily and 8 of 51 (16%) elderly patients receiving 20 mg twice daily. Of the approximately 12 000 patients enrolled in the Expanded Access Program, peripheral neuropathy or peripheral neuropathic symptoms developed in 30% of patients receiving 40 mg twice daily and 25% of patients receiving 20 mg twice daily. Elderly patients should be closely monitored for signs and symptoms of peripheral neuropathy.

ZERIT is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function. Dose adjustment is recommended for patients with renal impairment (see DOSAGE AND ADMINISTRATION: Dosage Adjustment).

ADVERSE REACTIONS

Adults

Fatal lactic acidosis has occurred in patients treated with ZERIT in combination with other antiretroviral agents. Patients with suspected lactic acidosis should immediately suspend therapy with ZERIT. Permanent discontinuation of ZERIT should be considered for patients with confirmed lactic acidosis.

ZERIT therapy has rarely been associated with motor weakness, occurring predominantly in the setting of lactic acidosis. If motor weakness develops, ZERIT should be discontinued

ZERIT therapy has also been associated with peripheral sensory neuropathy. which can be severe, is dose related, and occurs more frequently in patients being treated with other drugs that have been associated with neuropathy (including didanosine), in patients with advanced HIV infection, or in patients who have previously experienced peripheral neuropathy.

Patients should be monitored for the development of neuropathy which is usually manifested by numbness, tingling, or pain in the feet or hands. Stavudine-related peripheral neuropathy may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one-half the dose (see DOSAGE AND ADMINISTRATION). If neuropathy recurs after resumption, permanent discontinuation of ZERIT should be considered.

When ZERIT is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when ZERIT is used alone. Pancreatitis, peripheral neuropathy, and liver function abnormalities occur more frequently in patients treated with the combination of ZERIT and didanosine, with or without hydroxyurea. Fatal pancreatitis and hepatotoxicity may occur and hydroxyurea (see WARNINGS and PRECAUTIONS).

Selected clinical adverse events that occurred in adult patients receiving Antiretrovital Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women expected to stavudine and other antiretroviral agents, an Antiretroviral provided in Table 7.

Table 7 Selected Clinical Adverse Events in Study Al455-019ª (Monotherapy)
Percent (%)

	T Crocitt (70)		
Adverse Events	ZERIT ^b (40 mg twice daily) (n=412)	zidovudine (200 mg 3 times daily) (n=402)	
Headache	54	49	
Diarrhea	50	44	
Peripheral Neurologic			
Symptoms/Neuropathy	52	39	
Rash	40	35	
Nausea and Vomiting	39	44	

zidovudine therapy = 53 weeks

Pancreatitis was observed in 3 of the 412 adult patients who received ZERIT in a controlled monotherapy study. Selected clinical adverse events that occurred in antiretroviral-naive adult

atients receiving ZERIT from two controlled combination studies are provided in Table 8.

Table 8 Selected Clinical Adverse Events^a in START 1 and START 2^b Studies (Combination Therapy)

		Percent	I (%)	
_	STA	RT 1	STA	RT 2 ^b
Adverse Events	ZERIT + lamivudine + indinavir (n=100°)	zidovudine + lamivudine + indinavir (n=102)	ZERIT + didanosine + indinavir (n=102°)	zidovudine + lamivudine + indinavir (n=103)
Nausea	43	63	53	67
Diarrhea	34	16	45	39
Headache	25	26	46	37
Rash	18	13	30	18
Vomiting	18	33	30	35
Peripheral Ne	urologic Sympto	ms/		
Neuropathy	/ 8	7	21	10

Any severity, regardless of relationship to study regimen b START 2 compared two triple-combination regimens in 205 treatment-naive patients. Patients received either ZERIT (40 mg twice daily) plus didanosine plus indinavir or zidovudine plus lamivudine plus indinavir. Duration of stayudine therapy = 48 weeks.

Pancreatitis resulting in death was observed in patients treated with ZERIT plus didanosine, with or without hydroxyurea, in controlled clinical studies and in nostmarketing reports.

Selected laboratory abnormalities reported in a controlled monotherapy study (Study Al455-019) are provided in Table 9.

Table 9 Selected Adult Labo	oratory Abnormalities in	Study AI455-019 ^{a,b}
	Percer	nt (%)
Parameter	ZERIT (40 mg twice daily) (n=412)	zidovudine (200 mg 3 times daily) (n=402)
AST (SGOT) (>5.0 x ULN)	11	10
ALT (SGPT) (>5.0 x ULN)	13	11

Amvlase $(>14 \times UIN)$ Data presented for patients for whom laboratory evaluations were

Median duration of stavudine therapy = 79 weeks; median duration of zidovudine therapy = 53 weeks.

ULN = upper limit of normal.

Selected laboratory abnormalities reported in two controlled combination studies are provided in Tables 10 and 11

Table 10 Selected Laboratory Abnormalities in START 1 and START 2 Studies (Grades 3-4)

		Perc	ent (%)	
	STA	RT 1	S	TART 2
Parameter	ZERIT + lamivudine + indinavir (n=100)	zidovudine + lamivudine + indinavir (n=102)	ZERIT + didanosine + indinavir (n=102)	lamivudine + indinavir
Bilirubin	7	6	16	8
(>2.6 x ULN) AST (SGOT) (>5 x ULN)	5	2	7	7
ALT (SGPT) (>5 x ULN)	6	2	8	5
GGT (>5 x ULN)	2	2	5	2
(>3 x ULN) Lipase (>2 x ULN)	6	3	5	5
(>2 x ULN) Amylase (>2 x ULN)	4	<1	8	2

(All Grades)				
		Perc	ent (%)	
-	STAF	RT 1	STA	RT 2
Parameter	ZERIT + lamivudine + indinavir (n=100)	zidovudine + lamivudine + indinavir (n=102)	ZERIT + didanosine + indinavir (n=102)	zidovudine + lamivudine + indinavir (n=103)
Total Bilirubi	n 65	60	68	55
AST (SGOT)	42	20	53	20
ALT (SGPT)	40	20	50	18
GGT	15	8	28	12
Lipase	27	12	26	19
Amylase	21	19	31	17

The following events have been identified during post-approval use of ZERIT

distribution/accumulation of body fat (see PRECAUTIONS: Fat

Digestive Disorders—anorexia Exocrine Gland Disorders-pancreatitis [including fatal cases (see

WARNINGS)

Hematologic Disorders-anemia, leukopenia, thrombocytopenia, and macrocytosis. *Liver*—symptomatic hyperlactatemia/lactic acidosis and hepatic steatosis (see WARNINGS), hepatitis and liver failure.

Musculoskeletal—myalgia. Nervous System—insomnia severe motor weakness (most often

reported in the setting of lactic acidosis, see WARNINGS). **Pediatric Patients**

Adverse reactions and serious laboratory abnormalities in pediatric patients from birth through adolescence were similar in type and frequency to those seen in adult natients (see PRECAUTIONS: Pediatric Use)

OVERDOSAGE

Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Complications of chronic overdosage include peripheral neuropathy and hepatic toxicity. Stavudine can be removed by hemodialysis: the mean + SD hemodialysis clearance of stayudine is 120 ± 18 mL/min. Whether stavudine is eliminated by peritoneal dialysis has not been studied

DOSAGE AND ADMINISTRATION

The interval between doses of ZERIT (stavudine) should be 12 hours. ZERIT may be taken with or without food.

Adults: The recommended dose based on body weight is as follows: 40 mg twice daily for patients \geq 60 kg. 30 mg twice daily for patients <60 kg.

Pediatrics: The recommended dose for newborns from birth to 13 days old is 0.5 mg/kg/dose given every 12 hours (see CLINICAL PHARMACOLOGY) The recommended dose for pediatric patients at least 14 days old and weighing less than 30 kg is 1 mg/kg/dose, given every 12 hours. Pediatric patients weighing 30 kg or greater should receive the recommended adult dosage.

Dosage Adjustment

Patients should be monitored for the development of peripheral neuropathy, which is usually manifested by numbness, tingling, or pain in the feet or hands. These symptoms may be difficult to detect in young children (see WARNINGS). If these symptoms develop during treatment, stavudine therapy should be interrupted. Symptoms may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one-half the recommended dose: 20 mg twice daily for patients ≥60 kg.

15 mg twice daily for patients <60 kg.

If peripheral neuropathy recurs after resumption of ZERIT, permanent discontinuation should be considered.

Renal Impairment

ZERIT may be administered to adult patients with impaired renal function with adjustment in dose as shown in Table 12.

fable 12 Recommended	Dosage Adjustment for Rena	al Impairment	
Creatinine Clearance	Recommended ZERIT Dose by Patient Weight		
(mL/min)	≥60 kg	<60 kg	
>50	40 mg every 12 hours	30 mg every 12 hours	
26-50	20 mg every 12 hours	15 mg every 12 hours	
10–25	20 mg every 24 hours	15 mg every 24 hours	

Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with renal impairment. Although there are insufficient data to recommend a specific dose adjustment of ZERIT in this patient population, a reduction in the dose and/or an increase in the interval between doses should be considered. lemodialysis Patients

The recommended dose is 20 mg every 24 hours (≥60 kg) or 15 mg every 24 hours (<60 kg), administered after the completion of hemodialysis and at the

Prior to dispensing, the pharmacist must constitute the dry powder with purified water to a concentration of 1 mg stavudine per mL of solution, as follows:

<u>_; _; 0</u> ы

Tell Dr a 10 n of **al** if if

you Nad

2 0

		Percent (%)				
	STA	RT 1	START 2			
Parameter	ZERIT + lamivudine + indinavir (n=100)	zidovudine + lamivudine + indinavir (n=102)	ZERIT + didanosine + indinavir (n=102)			
Bilirubin	7	6	16	8		
(>2.6 x ULN) AST (SGOT) (>5 x ULN)	5	2	7	7		
ALT (SGPT) (>5 x ULN)	6	2	8	5		
GGT (>5 x ULN)	2	2	5	2		
Lipase (>2 x ULN)	6	3	5	5		
Amylase (>2 x ULN)	4	<1	8	2		

Table 11 Selected Laboratory Abnormalities in START 1 and START 2 Studies

-	(All Grades)						
		Percent (%)					
		STAF	RT 1	STA	START 2		
_	Parameter	ZERIT + lamivudine + indinavir (n=100)	zidovudine + lamivudine + indinavir (n=102)	ZERIT + didanosine + indinavir (n=102)	zidovudi lamivudi indina (n=10		
	Total Bilirubi AST (SGOT)	n 65 42	60 20	68 53	55 20		

Observed During Clinical Practice

(stavudine). Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to

Body as a Whole—abdominal pain, allergic reaction, chills/fever, and

7FRIT or a combination of these factors

same time of day on non-dialysis days. Method of Preparation ZERIT (stavudine) for Oral Solution Add 202 mL of purified water to the container.

1187086A2

2 Shake container vigorously until the powder dissolves completely. Constituti in this way produces 200 mL (deliverable volume) of 1 mg/mL stavudine solution. The solution may appear slightly hazy. 3. Dispense solution in original container with measuring cup provided. Instruct

patient to shake the container vigorously prior to measuring each dose and to store the tightly closed container in a refrigerator, 2° C to 8° C (36° F to 46° F). Discard any unused portion after 30 days.

HOW SUPPLIED

Product

Strength

15 mg

20 mg

30 mg

40 mg

ZERIT® (stavudine) Capsules are available in the following strengths and configurations of plastic bottles with child-resistant closures:

Table 13
Capsule Strength/Configuration

Capsul Shell Co		Markings on Capsule (in Black Ink)		Capsules per Bottle	NDC No.		
Light yell & dark r		BMS 1964	15	60	0003-1964-01		
Light bro	wn	BMS 1965	20	60	0003-1965-01		
Light orar & dark ora	nge Inge	BMS 1966	30	60	0003-1966-01		
Dark orar	nge	BMS 1967	40	60	0003-1967-01		

ZERIT® (stavudine) for Oral Solution is a dve-free, fruit-flavored powder that provides 1 mg of stavudine per mL of solution upon constitution with water. Directions for solution preparation are included on the product label and in the DOSAGE AND ADMINISTRATION section of this insert. ZEBIT for Oral Solution (NDC No. 0003-1968-01) is available in child-resistant containers that provide 200 mL of solution after constitution with water.

US Patent No · 4 978 655

ZERIT Capsules should be stored in tightly closed containers at 25° C (77° F). Excursions between 15° C and 30° C (59° F and 86° F) are permitted (see USP Controlled Boom Temperature)

7FBIT for Oral Solution should be protected from excessive moisture and stored in tightly closed containers at 25° C (77° F). Excursions between 15° C and 30° C (59° F and 86° F) are permitted (see USP Controlled Room Temperature). After constitution, store tightly closed containers of ZERIT for Oral Solution in a refrigerator, 2° C to 8° C (36° F to 46° F). Discard any unused portion after 30 days.

Bristol-Myers Squibb Company Princeton, NJ 08543 USA

Revised August 2006

let പ്ര Squn 8543